BioCentury
ARTICLE | Clinical News

Genentech reports ORR of 77.4% for entrectinib in pooled analysis of ROS1-positive NSCLC patients

October 5, 2018 8:32 PM UTC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported data from an integrated analysis of 53 patients with locally advanced or metastatic c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1)-positive non-small cell lung cancer (NSCLC) in the Phase II STARTRK-2 and the Phase I STARTRK-1 and ALKA trials showing that oral entrectinib (RXDX-101) led to an objective response rate (ORR) of 77.4%. The company said the duration of response was 24.6 months. In patients with CNS cancers, entrectinib led to an intracranial ORR of 55%. Data were presented at the World Conference on Lung Cancer in Toronto.

The analysis included patients from STARTRK-2, an open-label, global basket trial in patients with solid tumors harboring a neurotrophic tyrosine kinase receptor 1 (TrkA; NTRK1), TrkB, TrkC or ROS1 gene fusion; STARTRK-1, an open-label, dose-escalation, U.S. and South Korean trial in solid tumor patients with TrkA, TrkB, TrkC or ROS1 gene fusions; and ALKA, a dose-escalation, Italian trial in patients with advanced or metastatic solid tumors with ROS1 gene fusions...